Coenzyme Q10 in cardiovascular disease

Mitochondrion

Volumn 7, Issue SUPPL., 2007, Pages

  Pepe, Salvatore ^a,b,c   Marasco, Silvana F ^a,b,c   Haas, Steven J ^b   Sheeran, Freya L ^b,c   Krum, Henry ^b   Rosenfeldt, Franklin L ^a,b,c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Antioxidant; Cardiac surgery; Coenzyme Q10; Heart failure; Human; Hypertension; Ischaemic heart disease; Mitochondria; Statins; Ubiquinone

Indexed keywords

ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NIFEDIPINE; NITRATE; NITROPRUSSIDE SODIUM; PLACEBO; PROBUCOL; REACTIVE OXYGEN METABOLITE; UBIDECARENONE; VASODILATOR AGENT; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; DRUG DERIVATIVE; UBIQUINONE;

ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; FRIEDREICH ATAXIA; GENETIC CODE; HEART ARRHYTHMIA; HEART FAILURE; HEART MITOCHONDRION; HEART VALVE SURGERY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; MITOCHONDRIAL RESPIRATION; MONOTHERAPY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; BIOLOGICAL MODEL; CHEMISTRY; COENZYME; CONGESTIVE HEART FAILURE; DIET; ISCHEMIA; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY;

ADENOSINE TRIPHOSPHATE; ANTHRACYCLINES; ANTIOXIDANTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; COENZYMES; DIET; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; ISCHEMIA; MITOCHONDRIA; MODELS, BIOLOGICAL; UBIQUINONE;

EID: 34248217519     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2007.02.005     Document Type: Review

References (141)

1. Abu-Khalaf M.M., Juneja V., Chung G.G., Digiovanna M.P., Sipples R., McGurk M., Zelterman D., Haffty B., Reiss M., Wackers F.J., Lee F.A., and Burtness B.A. Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast. Cancer Res. Treat. (2006) [Epub ahead of print]
2. 10 and vitamin E on the peroxidation of human low density lipoprotein subfractions. Proc. Natl. Acad. Sci. USA 92 (1995) 9388-9391
3. Arbustini E., Diegoli M., Fasani R., Grasso M., Morbini P., Banchieri N., Bellini O., Dal Bello B., Pilotto A., Magrini G., Campana C., Fortina P., Gavazzi A., Narula J., and Vigano M. Mitochondrial DNA mutations and mitochondrial abnormalities in dilated cardiomyopathy. Am. J. Pathol. 153 (1998) 1501-1510
4. 2 is a candidate for the structural gene encoding para-hydroxybenzoate: polyprenyltransferase. J. Biol. Chem. 267 (1992) 4128-4136
5. Aw T.Y., Williams M.W., and Gray L. Absorption and lymphatic transport of peroxidized lipids by rat small intestine in vivo: role of mucosal GSH. Am. J. Physiol. 262 (1992) G99-G106
6. 10 and exercise training in chronic heart failure. Eur. Heart J. 27 (2006) 2675-2681
7. Belch J.J., Bridges A.B., Scott N., and Chopra M. Oxygen free radicals and congestive heart failure. Br. Heart J. 65 (1991) 245-248
8. Benderdour M., Charron G., de Blois D., Comte B., and Des Rosiers C. Cardiac Mitochondrial NADP+ - isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation. J. Biol. Chem. 278 (2003) 45154-45159
9. Benderdour M., Charron G., Comte B., Ayoub R., Beaudry D., Foisy S., de Blois D., and Des Rosiers C. Decreased mitochondrial NADP+ - isocitrate dehydrogenase activity and expression: a marker of oxidative stress in hypertropy development. Am. J. Physiol. 287 (2004) 2122-2131
10. 10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin. Cardiol. 27 (2004) 295-299
11. 10) (2001), Prominent Press, Scottsdale, Arizona 143-149
12. 10 in isolated systolic hypertension. South Med. J. 94 (2001) 1112-1117
13. 10 from myocardial reperfusion injury during coronary artery bypass grafting. Ann. Thorac. Surg. 58 (1994) 1427-1432
14. 10 on myocardial preservation during hypothermic cardioplegic arrest. J. Thorac. Cardiovasc. Surg. 107 (1994) 242-247
15. Choksi K.B., Boylston W.H., Rabek J.P., Widger W.R., and Papaconstantinou J. Oxidatively damaged proteins of heart mitochondrial electron transport complexes. Biochim. Biophys. Acta 1688 (2004) 95-101
16. 10 formulations. J. Am. Pharmaceut Assoc. 38 (1998) 262
17. 10 formulations in human subjects. Int. J. Vit. Nutr. Res. 68 (1998) 109-113
18. Cohn J.N. Foreward. In: Kukin M.L., and Fuster V. (Eds). Oxidative Stress and Cardiac Failure (2003), Futura Publishing Company, Armonk, NY vii-viii
19. 10 for prevention of anthracycline-induced cardiotoxicity. Integr. Cancer Ther. 4 (2005) 110-130
20. Constantinescu A., Maguire J.J., and Packer L. Interactions between ubiquinones and vitamins in membranes and cells. Mol. Aspects Med. 15 Suppl. (1994) S57-S65
21. 10 therapy. Biofactors 18 (2003) 163-171
22. Cracowski J.L., Tremel F., Marpeau C., Baguet J.P., Stanke-Labesque F., Mallion J.M., and Bessard G. Increased formation of F(2)-isoprostanes in patients with severe heart failure. Heart 84 (2000) 439-440
23. 10 in Golgi apparatus membrane redox activity and proton uptake. In: Folkers K., and Yamamura Y. (Eds). Biomedical and Clinical Aspects of Coenzyme Q (1984), Elsevier, Amsterdam 77-86
24. 10 pre-treatment. J. Thorac. Cardiovasc. Surg. 111 (1996) 443-450
25. De Pinieux G., Chariot P., Ammi-Said M., Louarn F., Lejonc J.L., Astier A., Jacotot B., and Gherardi R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br. J. Clin. Pharmacol. 42 (1996) 333-337
26. Dhalla A.K., and Singal P.K. Antioxidant changes in hypertrophied and failing guinea pig hearts. Am. J. Physiol. 266 (1994) H1280-H1285
27. Dhalla A.K., Hill M.F., and Singal P.K. Role of oxidative stress in transition of hypertrophy to heart failure. J. Am. Coll. Cardiol. 28 (1996) 506-514
28. Diaz-Velez C.R., Castineiras S.G., Mendoza-Ramos E., and Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am. Heart J. 131 (1996) 146-152
29. 10 on essential arterial hypertension. Curr. Ther. Res. 47 (1990) 841-845
30. 10 in essential hypertension. Curr. Ther. Res. 5 (1992) 668-672
31. 10 in essential hypertension. Mol. Aspects Med. 15 Suppl. (1994) S257-S263
32. Di Lisa F., Canton M., Menabo R., Dodoni G., and Bernardi P. Mitochondria and reperfusion injury. The role of permeability transition. Basic Res. Cardiol. 98 (2003) 235-241
33. 10) (2001), Prominent Press, Scottsdale, Arizona 1-111
34. Ernst A., Stolzing A., Sandig G., and Grune T. Antioxidants effectively prevent oxidation-induced protein damage in OLN 93 cells. Arch. Biochem. Biophys. 421 (2004) 54-60
35. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and Biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
36. Ferrara N., Abete P., Ambrosio G., Landino P., Caccese P., Cirillo P., Oradei A., Littarru G.P., Chiariello M., and Rengo F. Protective role of chronic ubiquinone administration on acute cardiac oxidative stress. J. Pharmacol. Exp. Ther. 274 (1995) 858-865
37. 10. Res. Commun. Chem. Path Pharmacol. 31 (1981) 129-139
38. 10. Proc. Natl. Acad. Sci. USA 82 (1985) 901-904
39. Fontaine E., Ichas F., and Bernardi P. A ubiquinone-binding site regulates the mitochondrial permeability transition pore. J. Biol. Chem. 273 (1998) 25734-25740
40. 2, a gene encoding a polyprenyl transferase involved in the synthesis of CoQ. Biochem. J. 382 (2004) 519-526
41. Frei B., Kim M.C., and Ames B.N. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc. Natl. Acad. Sci. USA 87 (1990) 4879-4883
42. Giordano F.J. Oxygen, oxidative stress, hypoxia and heart failure. J. Clin. Invest. 115 (2005) 500-508
43. Glinn M.A., Lee C.P., and Ernster L. Pro- and anti-oxidant activities of the mitochondrial respiratory chain: factors influencing NAD(P)H-induced lipid peroxidation. Biochem. Biophys. Acta 1318 (1997) 246-254
44. Go A.S., Lee W.Y., Yang J., Lo J.C., and Gurwitz J.H. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 17 (2006) 2105-2111
45. Groneberg D.A., Kindermann B., Althammer M., Klapper M., Vormann J., Littarru G.P., and Doring F. Coenzyme Q10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells. Int. J. Biochem. Cell Biol. 37 6 (2005) 1208-1218
46. Grunfeld S., Hamilton C.A., Mesaros S., McClain S.W., Dominiczak A.F., Bohr D.F., and Malinski T. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension 26 (1995) 854-857
47. 2+ overload during postischemic reperfusion. Am. J. Physiol. 266 (1994) H2174-H2181
48. Hill M.F., and Singal P.K. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am. J. Pathol. 148 (1996) 291-300
49. 10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur. J. Clin. Nutr. 56 (2002) 1137-1142
50. 10 Study Group. J. Card. Fail. (1995) 101-107
51. 2+ channel function during acute hypoxia. Cardiovasc. Res. 67 (2005) 624-635
52. Humphries K.M., Yoo Y., and Szweda L.I. Inhibition of NADH-linked mitochondrial respiration by 4-hydroxy-2-nonenal. Biochemistry 37 (1998) 552-557
53. Humphries K.M., and Szweda L.I. Selective inactivation of α-ketoglutarate dehydrogenase and pyruvate dehydrogenase: reaction of lipoic acid 4-hydroxy-2-nonenal. Biochemistry 37 (1998) 15835-15841
54. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., Uchida K., Arimura K.I., Egashira K., and Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85 (1999) 857-863
55. Ide T., Tsutsui H., Kinugawa S., Suematsu N., Hayashidani S., Ichikawa K., Utsumi H., Machida Y., Egashira K., and Takeshita A. Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ. Res. 86 (2000) 152-157
56. Jarreta D., Orus J., Barrientos A., Miro O., Roig E., Heras M., Moraes C.T., Cardellach F., and Cascademont J. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc. Res. 45 (2000) 860-865
57. 3, a gene encoding a methyltransferase required for ubiquinone biosynthesis. J. Biol. Chem. 275 (2000) 12381-12387
58. 10 during heart surgery. Clin. Invest. 71 (1993) 155-161
59. 10: absorption, antioxidative properties, determinants, and plasma levels. Free Radic. Res. 36 (2002) 389-397
60. Kalen A., Appelkvist E.L., and Dallner G. Age-related changes in the lipid compositions of rat and human tissues. Lipids 24 (1989) 579-584
61. 10 on exercise tolerance in chronic stable angina pectoris. Am. J. Cardiol. 56 (1985) 247-251
62. Kaul N., Siveski-Iliskovic N., Thomas T.P., Hill M., Khaper N., and Singal P.K. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 11 (1995) 551-554
63. Keith M., Geranmayegan A., Sole M.J., Kurian R., Robinson A., and Omran A.S. Increased oxidative stress in patients with congestive heart failure. J. Am. Coll. Cardiol. 31 (1998) 1352-1356
64. 10 therapy in class II and III systolic heart failure. Heart Lung Circ. J. 12 (2003) 135-141
65. 10 in patients with congestive heart failure. Ann. Int. Med. 132 (2000) 636-640
66. Koska J., Syrova D., Blazicek P., Marko M., Grna J.D., Kvetnansky R., and Vigas M. Malondialdehyde, lipofuscin and activity of antioxidant enzymes during physical exercise in patients with essential hypertension. J. Hypertens. 17 (1999) 529-535
67. In: Kukin M.L., and Fuster V. (Eds). Oxidative Stress and Cardiac Failure (2003), Futura Publishing Company, Armonk, NY
68. 10. Proc. Natl. Acad. Sci. USA 82 (1985) 4240-4244
69. 10. Mol. Aspects Med. 15 Suppl. (1994) S265-S272
70. 10. A review of animal and human publications. Biofactors 18 (2003) 101-111
71. Lawen A., Martinius R.D., McMullen G., Nagley P., Vaillant F., Wolvetang E.J., and Linnane A.W. The universality of bioenergetic disease: the role of mitochondrial mutation and the putative inter-relationship between mitochondria and plasma membrane NADH oxidoreductase. Mol. Aspects Med. 15 (1994) S13-S27
72. Lenaz G., Fato R., Castelluccio C., Cavazzoni M., Estornell E., Huertas J.F., Pallotti F., Parenti Castelli G., and Rauchova H. An updating of the biochemical function of coenzyme Q in mitochondria. Mol. Aspects Med. 15 Suppl. (1994) S29-S36
73. Lesnefsky E.J., Moghaddas S., Tandler B., Kerner J., and Hoppel C.L. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging and heart failure. J. Mol. Cell Cardiol. 33 (2001) 1065-1089
74. Li Y., Huang T.T., Carlson E.J., Melov S., Ursell P.C., Olson J.L., Noble L.J., Yoshimura M.P., Berger C., Chan P.H., Wallace D.C., and Epstein C.J. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat. Genet. 11 (1995) 376-381
75. 10 supplementation on human skeletal muscle. Free Radic. Res. 36 (2002) 445-453
76. Lucas D.T., and Szweda L.I. Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc. Natl. Acad. Sci. USA 96 (1999) 6689-6693
77. Lucas D.T., Aryal P., Szweda L.I., Koch W.J., and Leinwand L.A. Alterations in mitochondrial function in a mouse model of hypertrophic cardiomyopathy. Am. J. Physiol. 284 (2003) H575-H583
78. Luo X., Pitkanen S., Kassovska-Bratinova S., Robinson B.H., and Lehotay D.C. Excessive formation of hydroxyl radicals and aldehydic lipid peroxidation products in cultured skin fibroblasts from patients with Complex I deficiency. J. Clin. Invest. 99 (1997) 2882-2887
79. Mak S., Lehotay D.C., Yazdanpanah M., Azevedo E.R., Liu P.P., and Newton G.E. Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. J. Card Fail 6 (2000) 108-114
80. 2a in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation. 97 (1998) 1536-1539
81. Mariotti C., Solari A., Torta D., Marano L., Fiorentini C., and Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology 60 (2003) 1676-1679
82. 10 supplement renders swine hearts resistant to ischemia-reperfusion injury. Am. J. Physiol. Heart. Circ. Physiol. 278 (2000) H1084-H1090
83. McMurray J., McLay J., Chopra M., Bridges A., and Belch J.F. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 65 (1990) 1261-1262
84. 10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim. Biophys. Acta 1126 (1992) 247-254
85. Mohr D., Umeda Y., Redgrave T.G., and Stocker R. Antioxidant defenses in rat intestine and mesenteric lymph. Redox Rep. 4 (1999) 79-87
86. 10 supplements available in New Zealand differs markedly. New Zealand Med. J. 117 1203 (2004) 1-6
87. 10 in borderline hypertensive patients: a hemodynamic study. In: Folkers K., Littarru G.P., and Yamagami T. (Eds). Biomedical and Clinical Aspects of Coenzyme Q (1991), Elsevier Science Publishers, Amsterdam, North Holland 417-424
88. Morisco C., Trimarco B., and Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multi-center randomized study. Clin. Invest. 71 Suppl. (1993) S134-S136
89. 10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio" - a multinational trial. Biofactors 18 (2003) 79-89
90. 10 treatment in serious heart failure. Biofactors 9 (1999) 285-289
91. 10 (1980), Elsevier/North-Holland Biochemical Press 3-13
92. 10 (1980), Elsevier/North-Holland Biomedical Press, Amsterdam 409-424
93. 10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property. J. Biol. Chem. 278 (2003) 28220-28228
94. 10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur. Heart J. 13 (1992) 1528-1533
95. Pitkanen S., and Robinson B.H. Mitochondrial Complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J. Clin. Invest. 98 (1996) 345-351
96. Poehlman E.T., Scheffers J., Gottlieb S.S., Fisher M.L., and Vaitekevicius P. Increased resting metabolic rate in patients with congestive heart failure. Ann. Int. Med. 121 (1994) 860-862
97. 10 on left ventricular function in patients with dilative cardiomyopathy. Curr. Therapeut. Res. 49 (1991) 878-886
98. 10 protects the aging heart against stress: studies in rats, human tissues and patients. Ann. N.Y. Acad. Sci. 959 (2002) 355-359
99. 10 in physical exercise, hypertension and heart failure. Biofactors 18 (2003) 91-100
100. 10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. J. Thorac. Cardiovasc. Surg. 129 (2005) 25-32
101. 10 in the treatment of hypertension: a meta-analysis of the clinical trials. J. Hum. Hypertens. 21 (2007) 297-306
102. Sam F., Kerstetter D.L., Pimental D.R., Mulukutla S., Tabaee A., Bristow M.R., Colucci W.S., and Sawyer D.B. Increased reactive oxygen species production and functional alterations in antioxidant enzymes in human failing myocardium. J. Card. Fail. 11 (2005) 473-480
103. 10 on systolic function in patients with chronic heart failure. J. Card. Fail. 12 6 (2006) 464-472
104. 10 (1985), Elsevier, Amsterdam 385-394
105. Scheubel R.J., Tostlebe M., Simm A., Rohrbach S., Prondzinsky R., Gellerich F.N., Silber R.E., and Holtz J. Dysfunction of mitochondrial respiratory chain Complex I in human failing myocardium is not due to disturbed mitochondrial gene expression. J. Am. Coll. Cardiol. 4 (2002) 2174-2181
106. Sharov V.G., Goussev A., Lesch M., Goldstein S., and Sabbah H.N. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J. Mol. Cell Cardiol. 30 (1998) 1757-1762
107. Sharov V.G., Todor A.V., Silverman N., Goldstein S., and Sabbah H.N. Abnormal mitochondrial respiration in failed human myocardium. J. Mol. Cell Cardiol. 32 (2000) 2361-2367
108. 10 on myocardial metabolism and hemodynamics in open heart surgery. Kyobu Geka 36 (1983) 268-271 (In Japanese)
109. Singal P.K., Dhalla A.K., Hill M., and Thomas T.P. Endogenous antioxidant changes in the myocardium in response to acute and chronic stress conditions. Mol. Cell Biochem. 129 (1993) 179-186
110. Singal P.K., Siveski-Iliskovic N., Hill M., Thomas T.P., and Li T. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell Cardiol. 27 (1995) 1055-1063
111. 10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J. Hum. Hypertens. 13 (1999) 203-208
112. 10 illuminated by meta-analysis of clinical trials. Mol. Aspects Med. 18 Suppl. (1997) S159-S168
113. Stocker R., Bowry V.W., and Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc. Natl. Acad. Sci. USA 88 (1991) 1646-1650
114. Stocker R., and Suarna C. Extracellular reduction of ubiquinone-1 and -10 by human Hep G2 and blood cells. Biochem. Biophys. Acta 88 (1993) 1646-1650
115. 10 to enhance intraoperative myocardial protection in coronary artery revascularization. Cardiovasc. Drug Ther. 5 (1991) S297-S300
116. 10 on myocardial protection during cardiac operations. Ann. Thorac. Surg. 61 (1996) 829-833
117. 10: the prophylactic effect on low cardiac output following cardiac valve replacement. Ann. Thorac. Surg. 33 (1982) 145-151
118. Tokarska-Schlattner M., Wallimann T., and Schlattner U. Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin. C. R. Biol. 329 9 (2006) 657-668
119. 10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic. Biol. Med. 27 (1999) 1027-1032
120. 10 in humans. Int. J. Pharmacol. Therap. Toxicol. 24 (1986) 536-541
121. Turrens J.F. Superoxide production by the mitochondrial respiratory chain. Biosci. Rep. 17 (1997) 3-8
122. Turrens J.F., and Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191 (1980) 421-427
123. Turrens J.F., Alexandre A., and Lehninger A.L. Ubisemiquinone is the electron donor for superoxide formation by Complex III of heart mitochondria. Arch. Biochem. Biophys. 237 (1985) 408-414
124. Udell J.A., and Ray J.G. Primary and secondary prevention of heart failure with statins. Expert Rev. Cardiovasc. Ther. 4 6 (2006) 917-926
125. Vajo Z., King L.M., Jonassen T., Wilkin D.J., Ho N., Munnich A., and Clarke C.A. Conservation of the Caenorhabditis elegans timing gene clk-1 from yeast to human: a gene required for ubiquinone biosynthesis with potential implications for aging. Mamm. Genome 10 (1999) 1000-1004
126. van Dalen E.C., Caron H.N., Dickinson H.O., and Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 1 (2005) CD003917
127. Villalba J.M., Navarro F., Gomez-Diaz C., Arroyo A., Bello R.I., and Navas P. Role of cytochrome b5 reductase on the antioxidant function of coenzyme Q in the plasma membrane. Mol. Aspects Med. 18 Suppl. (1997) S7-S13
128. Walter L., Nogueira V., Leverve X., Heitz M.P., Bernardi P., and Fontaine E. Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site. J. Biol. Chem. 275 (2000) 29521-29527
129. 10 on left ventricular function in patients with congestive heart failure. J. Am. Coll. Cardiol. 33 (1999) 1549-1552
130. 10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 45 (2002) 420-426
131. 10 in human blood plasma. Int. J. Vit. Nutr. Res. 64 (1994) 311-315
132. 10 in a meal or as capsules to healthy subjects. Nutr. Res. 17 (1997) 941-945
133. 10 as therapy for myocardial ischemia reperfusion injury. Mol. Aspects Med. 18 Suppl. (1997) S195-S203
134. Wing L.M., Reid C.M., Ryan P., Beilin L.J., Brown M.A., Jennings G.L., Johnston C.I., McNeil J.J., Macdonald G.J., Marley J.E., Morgan T.O., and West M.J. Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348 7 (2003) 583-592
135. Wouters K.A., Kremer L.C., Miller T.L., Herman E.H., and Lipshultz S.E. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131 (2005) 561-578
136. 10 and essential hypertension. Res. Commun. Chem. Path Pharmacol. 11 (1975) 273-287
137. 10 to patients with essential hypertension. Res. Commun. Chem. Path Pharmacol. 14 (1976) 721-727
138. 10 in essential hypertension. In: Folkers K., and Yarnamura Y. (Eds). Biomedical and Clinical Aspects of Coenzyme Q (1977), Elsevier, Biomedical Press, North Holland 231-242
139. 10 on essential hypertension: a double blind controlled study. In: Folkers K., and Yamamura Y. (Eds). Biomedical and Clinical Aspects of Coenzyme Q (1986), Elsevier Science Publishers BV, Amsterdam, North Holland 337-343
140. Zhang Y., Aberg F., Appelkvist E.L., Dallner G., and Ernster L. Uptake of dietary coenzyme Q supplement is limited in rats. J. Nutr. 125 (1995) 446-453
141. 10 on myocardial protection during cardiac valve replacement and scavenging free radical activity in vitro. J. Cardiovasc. Surg. 40 (1999) 355-361